Brightline-1: MDM2 Inhibitor BI 907828 for the First Line Treatment of MDM2-Mutant Advanced or Metastatic Dedifferentiated Liposarcoma

Condition: Dedifferentiated Liposarcoma

Sponsor: Boehringer Ingelheim

Full Title
1403-0008: A Phase II/III, randomized, open-label, multi-centre study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcoma

Study Treatment
Oral MDM2 inhibitor BI 907828 vs doxorubicin

Eligibility/Info
For the treatment of patients with an MDM2-mutant, TP53 wild type dedifferentiated liposarcoma that has not yet been treated in the advanced/metastatic setting.

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.